Abstract
Considerable advances in the understanding of the immune basis of type I diabetes have encouraged trials of a number of forms of immunotherapy. Preliminary evidence indicates that cyclosporin (Sandimmune) treatment can halt beta cell destruction in about 50% of patients with newly diagnosed type I diabetes. Further studies are necessary to define the toxicity of this and other protocols prior to clinical use. Efforts to define the target antigen in type I diabetes may lead to development of more specific forms of immunotherapy or, possibly, a vaccine.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Autoantibodies / analysis
-
Clinical Trials as Topic
-
Cyclosporins / adverse effects
-
Cyclosporins / therapeutic use
-
Diabetes Mellitus, Type 1 / diagnosis
-
Diabetes Mellitus, Type 1 / immunology
-
Diabetes Mellitus, Type 1 / prevention & control
-
Diabetes Mellitus, Type 1 / therapy*
-
Glucose Tolerance Test
-
Humans
-
Immunotherapy*
-
Insulin Antibodies / analysis
-
Kidney / drug effects
Substances
-
Autoantibodies
-
Cyclosporins
-
Insulin Antibodies
-
islet cell antibody